Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A practice tool for the new oral anticoagulants.

Literature DB >> 24494013

A practice tool for the new oral anticoagulants.

Anne Massicotte¹.

Abstract

Year: 2014 PMID： 24494013 PMCID： PMC3908617 DOI： 10.1177/1715163513513869

Source DB: PubMed Journal: Can Pharm J (Ott) ISSN： 1715-1635

× No keyword cloud information.

11 in total

1. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

Authors: Yu Chen Barrett; Zhaoqing Wang; Charles Frost; Andrew Shenker
Journal: Thromb Haemost Date: 2010-10-26 Impact factor: 5.249

Review 2. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.

Authors: Sam Schulman; Mark A Crowther
Journal: Blood Date: 2012-02-01 Impact factor: 22.113

Review 3. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.

Authors: James D Douketis
Journal: Curr Pharm Des Date: 2010 Impact factor: 3.116

Review 4. Laboratory assessment of new anticoagulants.

Authors: Meyer M Samama; Céline Guinet
Journal: Clin Chem Lab Med Date: 2011-02-03 Impact factor: 3.694

Review 5. Reversal of antithrombotic agents.

Authors: Kenneth A Bauer
Journal: Am J Hematol Date: 2012-03-28 Impact factor: 10.047

Review 6. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Authors: Scott Kaatz; Peter A Kouides; David A Garcia; Alex C Spyropolous; Mark Crowther; Jim D Douketis; Anthony K C Chan; Andra James; Stephan Moll; Thomas L Ortel; Elizabeth M Van Cott; Jack Ansell
Journal: Am J Hematol Date: 2012-04-04 Impact factor: 10.047

7. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors: Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal: Clin Pharmacokinet Date: 2010-04 Impact factor: 6.447

Review 8. How I treat anticoagulated patients undergoing an elective procedure or surgery.

Authors: Alex C Spyropoulos; James D Douketis
Journal: Blood Date: 2012-08-28 Impact factor: 22.113

Review 9. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

Authors: Marta A Miyares; Kyle Davis
Journal: Am J Health Syst Pharm Date: 2012-09-01 Impact factor: 2.637

A practice tool for the new oral anticoagulants.

1. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

Review 2. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.

Review 3. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.

Review 4. Laboratory assessment of new anticoagulants.

Review 5. Reversal of antithrombotic agents.

Review 6. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

7. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Review 8. How I treat anticoagulated patients undergoing an elective procedure or surgery.

Review 9. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

Review 10. Novel oral anticoagulants: implications in the perioperative setting.

1. Checklists for the use of novel oral anticoagulants by the front-line clinician.

2. Accurate GFR in obesity-protocol for a systematic review.

Review 3. Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide.

4. Spinal Cord Compression Secondary to a Spontaneous Spinal Haematoma in a Patient Newly Treated with Rivaroxaban.